Impact Of Alectinib On Survival After Crizotinib Failure In Alk-Positive Nsclc Patients

e19138 Background: The next generation ALK inhibitor, alectinib, reportedly has potent efficacy after crizotinib failure in ALK-positive NSCLC patients. In the present study, we investigated progression patterns at crizotinib failure and clinical outcome after crizotinib failure, and evaluated the impact of progression patterns and alectinib on survival after crizotinib failure. Methods: Among a total of 76 ALK-positive NSCLC patients who underwent chemotherapy from January 2010 to December 2014 at our institution, 71 were treated with ALK inhibitors, 49 of whom were treated with crizotinib as the initial ALK inhibitor. We retrospectively evaluated these 49 patients for baseline characteristics, initial response to crizotinib, initial progression sites, treatment after crizotinib and post progression survival (PPS) from Response Evaluation Criteria in Solid Tumors- progressive disease (RECIST-PD) on crizotinib. Results: Of the 49 patients treated with crizotinib, 18 (37%) were male, median age was 52 year...